Beyond liver cancer, it is important to assess whether SARAF’s potential tumor-suppressive function is conserved in other malignancies characterized by dysregulated calcium signaling, such as breast cancer and colorectal cancer [9,26,46]. This evidence concerns the gene SARAF and colorectal cancer.